echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Guizhou Bailing accelerates the promotion of Miao medicine project through "medical linkage"

    Guizhou Bailing accelerates the promotion of Miao medicine project through "medical linkage"

    • Last Update: 2021-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In order to sell its products for the treatment of diabetes sugar Ningtong capsules, Guizhou Bailing in recent years is obsessively invested in the construction of diabetes specialist hospitals. Recently, Guizhou Bailing announced that it intends to use the over-funded 49.85 million yuan investment to expand its wholly-owned subsidiary Guizhou Bailing Chinese Medicine Diabetes Hospital Co., Ltd. It is worth noting that the diabetes hospital in Bailing, Guizhou, is in a loss-making state all the year after year. According to the analysis, pharmaceutical companies often choose to buy or expand hospitals to sell drugs, but due to the particularity of pharmaceutical preparations, Guizhou Bailing wants to divide the diabetes market through this way need more effort.the market
    diabetes, hypertension and other chronic drugs market demand increased, so that Guizhou Bailing and many other enterprises into the field of slow disease market hope to get a piece of the pie. Recently, Guizhou Bailing issued a notice that the company intends to use the super-funded 49.85 million yuan investment to expand the wholly-owned subsidiary Guizhou Bailing Chinese Medicine Diabetes Hospital Co., Ltd.
    Beijing Business Daily reporter learned that Guizhou Bailing in recent years in the layout of diabetes hospital movements frequently. Public information shows that in 2013, Guizhou Bailing High Premium acquired Tianyuan Hospital, increased its capital to transform the diabetes specialist hospital Guizhou Bailing, and in January 2015, Guizhou Bailing and Hunan Shanputang Investment Management Co., Ltd. jointly invested 250 100,000 yuan, in Changsha City, the establishment of Guizhou Bailing Chinese Medicine Diabetes (Changsha) Hospital, in May 2015, the company and Yunnan White Pharmaceutical Group Chinese Medicine Resources Co., Ltd. signed a "Group Strategic Cooperation Agreement" on the two sides in diabetes specialist hospitals and other projects.
    Jiang Wei, chairman of Guizhou Bailing, said publicly earlier that Guizhou Bailing has the exclusive miao medicine product for the treatment of diabetes, sugar Ningtong capsule, and around this product investment to establish a diabetes specialist hospital, thus opening the "pharmaceutical linkage" strategy.the special status of
    preparation medicine of the self-sufficient sugar Ningtong capsule medical institution is the main reason for Guizhou Bailing's obsession with the layout of the hospital. Public information shows that Guizhou Bailing's sugar Ningtong-Tongtong capsule obtained the "Medical Institution Preparation Registration Approval" issued by the Guizhou Food and Drug Administration and the "Medical Institution Practice License" issued by the Guizhou Administration of Traditional Chinese Medicine to serve diabetic patients in the form of hospital preparations. This means that the product needs to be sold in a hospital.
    analyst, who did not want to be named, said hospital preparations such as sugar-ning tonglu capsules could also be sold in other hospitals, but it would also depend on whether other hospitals were willing to buy them. It's better to ask for people than to ask for yourself, Guizhou Bailing should want to build its own hospital to sell medicines.
    , Beijing Business Daily reporter found that although has been committed to hospital investment and construction, but Guizhou Bailing Diabetes Hospital performance is not optimistic. Financial data show that in 2016, Guiyang Diabetes Lost 11.1885 million yuan, in the first half of 2017, Guiyang Diabetes Hospital lost 4.16 million yuan, Changsha Diabetes Hospital lost 3.07 million yuan.
    , Guizhou Bailing related officials in an interview with the Beijing Business Daily, said changsha diabetes hospital losses mainly because the hospital was just established. Guiyang Diabetes Hospital is actually profitable, but because the hospital can not produce drugs, by the parent company for production, the hospital needs to pay commissioned processing fees and trademark licensing fees, so the financial report shows a loss.
    the above-mentioned relevant person in charge said that the future of Guizhou Bailing Chinese Medicine Diabetes Hospital will be diabetes treatment as the core, and for all kinds of complications involved in diabetes, supporting the establishment of relevant professional departments, to build a complete industrial chain of diabetes treatment.of funding
    in early 2015, sugar Ning Tongtong capsule successfully obtained the medical institution preparation approval, in Guizhou Bailing Chinese medicine diabetes hospital put into use. Some analysts believe that, although self-built hospitals can solve the problem of drug sales channels, but relying on medical institutions to produce and sell products profit is too low, not enough as a pharmaceutical companies to support the profit point.
    Zhao Heng, founder of latitudeHealth, a medical strategy consulting firm, said in an interview with the Beijing Business Daily that the essence of pharmaceutical companies buying or expanding hospitals is to sell drugs, but only if they have enough hospitals, which require greater capital costs, and Guizhou Bailing should be able to get some development through this approach, but it is difficult to do so.
    Guizhou Bailing related person in charge said that in the future, the company will continue to build their own Chinese medicine diabetes hospital "medical linkage" model and with other hospitals jointly developed "hospital-enterprise joint" model two-wheel drive, accelerate the promotion of the integration of Miao medicine project. (Beijing Business Daily)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.